Fresenius Medical Care AG is under investigation by the U.S. Federal Trade Commission $(FTC.UK)$ over potential antitrust violations. The inquiry focuses on whether FMC and its competitor, DaVita, have unlawfully hindered smaller competitors in the dialysis sector. Allegations suggest that both companies may have made it difficult for physicians working in their clinics to establish their own practices or move to competing providers, particularly through non-compete agreements affecting nephrologists. The investigation is still in its early stages. This scrutiny comes amid broader concerns over FMC's corporate governance and recent labor unrest related to union-busting activities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.